CFCarlos Ferrándiz

Carlos Ferrándiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Ferrándiz has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Challenges for new adopters in pre-surgical margin assessment by handheld reflectance confocal microscope of basal cell carcinoma; a prospective single-center study

    by Nina Richarz, Aram Boada, Ane Jaka, Julio Bassas, Carlos Ferrandiz, Jose Manuel Carrascosa, Oriol Yélamos

    Citation: Richarz NA, Boada A, Jaka A, et al. UV Irradiation of Nevi: Impact on Performance of Electrical Impedance Spectroscopy and a Convolution Neural Network. Dermatol Pract Concept. 2022;12(4):e2022162. DOI: https://doi.org/10.5826/dpc.1204a162 Accepted: February 9, 2022; Published: October 2022 Copyright: ©2022 Richarz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Nina A. Richarz, MD, Department of Dermatology University Hospital Germans Trias i Pujol. Address: Carretera de Canyet s/n, 08916 Badalona, Barcelona, Spain. Phone: +34 934651200 E-mail: richarznina@gmail.com Introduction: In vivo reflectance confocal microscopy (RCM) is a useful tool for assessing pre-surgical skin tumor margins when performed by a skilled, experienced user. The technique, however, poses significant challenges to novice users, particularly when a handheld RCM (HRCM) device is used. Objective: To evaluate the performance of an HRCM device operated by a novice user to delineate basal cell carcinoma (BCC) margins before Mohs micrographic surgery (MMS) Methods: We performed a prospective study of 17 consecutive patients with a BCC in a high-risk facial area (the H zone) in whom tumor margins were assessed by HRCM and dermoscopy before MMS. Predicted surgical defect areas (cm2) were calculated using standardized photographic digital documentation and compared to final defect areas after staged excision. Results: No significant differences were observed between median HRCM-predicted and observed surgical defect areas (2.95 cm2 [range: 0.83–17.52] vs 2.52 cm2 [range 0.71–14.42]; p=0.586). Dermoscopy, by contrast, produced significantly underestimated values (median area of 1.34 cm2 [0.41-4.64] vs 2.52 cm2 [range 0.71-14.42]; pConclusion: Even in the hands of a novice user, HRCM is more accurate than dermoscopy for delineating lateral BCCs margins in high-risk areas and performs well at predicting final surgical defects. Keywords : reflectance confocal microscopy, basal cell carcinoma, micrographic Mohs surgery, margin control This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Open Access

    Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: A Multicenter Propensity Score Matching Study

    by Antonio Tejera-Vaquerizo, Aram Boada, Simone Ribero, Susana Puig, Sabela Paradela, David Moreno-Ramírez, Javier Cañueto, Blanca de Unamuno-Bustos, Ana Brinca, Miguel A. Descalzo-Gallego, et al.

    The therapeutic value of sentinel lymph node biopsy (SLNB) in thin melanoma remains controversial. The aim of this study is to determine the role of SLNB in the survival of thin melanomas (≤1 mm). A multicenter retrospective observational study was designed. A propensity score matching was performed to compare patients who underwent SLNB vs. observation. A multivariate Cox regression was used. A total of 1438 patients were matched by propensity score. There were no significant differences in melanoma-specific survival (MSS) between the SLNB and observation groups. Predictors of MSS in the multivariate model were age, tumor thickness, ulceration, and interferon treatment. Results were similar for disease-free survival and overall survival. The 5- and 10-year MSS rates for SLN-negative and -positive patients were 98.5% vs. 77.3% (p < 0.001) and 97.3% vs. 68.7% (p < 0.001), respectively. SLNB does not improve MSS in patients with thin melanoma. It also had no impact on DSF or OS. However, a considerable difference in MSS, DFS, and OS between SLN-positive and -negative patients exists, confirming its value as a prognostic procedure and therefore we recommend discussing the option of SLNB with patients.


  • Open Access

    Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort

    by C Hernández-Fernández, G Carretero, R Rivera, C Ferrándiz, E Daudén, P Cueva, I Belinchón, F Gómez-García, E Herrera-Acosta, D Ruiz-Genao, et al.

    The effect of gender on systemic therapy for psoriasis has not been well studied. The aim of this st...


  • Age as a prognostic factor in thick and ultrathick melanomas without lymph node metastasis

    by A. Boada, A. Tejera‐Vaquerizo, S. Ribero, S. Puig, D. Moreno‐Ramírez, S. Osella‐Abate, P. Cassoni, J. Malvehy, S. Podlipnik, C. Requena, et al.

    The presence of regional metastasis is a predictor of worse survival in thick melanoma1 and is currently an indication for adjuvant therapy. Few studies have analyzed the prognostic role of clinical and pathologic variables in thick melanoma without metastatic lymph node involvement2‐4. The aim of this study was to identify them.


  • Factors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanoma

    by Aram Boada, Antonio Tejera-Vaquerizo, Simone Ribero, Susana Puig, David Moreno-Ramírez, Pietro Quaglino, Simona Osella-Abate, Paola Cassoni, Josep Malvehy, Cristina Carrera, et al.


  • Open Access

    Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study

    by Aram Boada, Antonio Tejera‐Vaquerizo, Simone Ribero, Susana Puig, David Moreno‐Ramírez, Miguel A. Descalzo‐Gallego, María T. Fierro, Pietro Quaglino, Cristina Carrera, Josep Malvehy, et al.

    The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow‐up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI) 0.61–0.90); p = 0.002] and OS (AHR, 0.75; 95% CI, 0.60–0.94; p = 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65–1.08; p = 0.165). SLN‐negative patients had better 5‐ and 10‐year MSS compared with SLN‐positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p = 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.